loader
Please Wait
Applying Filters...

Approved Marketing Authorisations (MA) containing Mepolizumab in Europe. Original Data : EMA Website

Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 4GlaxoSmithKline AG

02 1GlaxoSmithKline Trading

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

Boulder Peptide 2024
Not Confirmed
arrow
arrow
Boulder Peptide 2024
Not Confirmed

Mepolizumabum

Brand Name : Nucala

Dosage Form : Dry Sub

Dosage Strength : 100mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

02

Boulder Peptide 2024
Not Confirmed
arrow
arrow
Boulder Peptide 2024
Not Confirmed

Mepolizumabum

Brand Name : Nucala

Dosage Form : Inj L?s

Dosage Strength : 100mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

03

Boulder Peptide 2024
Not Confirmed
arrow
arrow
Boulder Peptide 2024
Not Confirmed

Mepolizumabum

Brand Name : Nucala

Dosage Form : Inj L?s

Dosage Strength : 100mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

04

Boulder Peptide 2024
Not Confirmed
arrow
arrow
Boulder Peptide 2024
Not Confirmed

Mepolizumabum

Brand Name : Nucala

Dosage Form : Inj L?s

Dosage Strength : 100mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

05

GlaxoSmithKline Trading

Country
Boulder Peptide 2024
Not Confirmed
arrow

GlaxoSmithKline Trading

Country
arrow
Boulder Peptide 2024
Not Confirmed

mepolizumab

Brand Name : Nucala

Dosage Form : POWDER FOR SOLUTION FOR INJECTION

Dosage Strength : 100 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank